JO3274B1 - أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري - Google Patents

أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري

Info

Publication number
JO3274B1
JO3274B1 JOP/2010/0453A JOP20100453A JO3274B1 JO 3274 B1 JO3274 B1 JO 3274B1 JO P20100453 A JOP20100453 A JO P20100453A JO 3274 B1 JO3274 B1 JO 3274B1
Authority
JO
Jordan
Prior art keywords
human
hyperlipidemia
protein
hangptl4
antibodies
Prior art date
Application number
JOP/2010/0453A
Other languages
English (en)
Inventor
Chen Gang
H Kim Jee
Gusarova Viktoria
W Sleeman Mark
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3274B1 publication Critical patent/JO3274B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Radiology & Medical Imaging (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير جسم مضاد بشري تام أو شظية ربط مولد ضد للجسم المضاد البشري الذي يرتبط على وجه التحديد ببروتين شبيه مكون الأوعية البشري 4 (hANGPTL4) وتثبيطه. تعد الأجسام المضادة hANGPTL4 البشرية مفيدة في علاج الأمراض والاضطرابات المرتبطة بـ ANGPTL4، مثل فرط الشحوم في الدم، وفرط بروتينات الدم الشحمية واختلال نسبة الدهون في الدم، بما في ذلك فرط الجليسريدات الثلاثية في الدم، وفرط الكوليسترول في الدم، ووجود الكيلو مكرونات في الدم، وما إلى ذلك. علاوة على ذلك، يمكن إعطاء الأجسام المضادة hANGPTL4 لمريض بحاجة لها لمنع أو علاج الأمراض والاضطرابات، والتي يمثل اضطراب أيض الشحوم عامل خطورة لها. تتضمن تلك الأمراض والاضطرابات أمراض الأوعية القلبية، مثل التصلب العصيدي، وأمراض الشريان التاجي، والتهاب البنكرياس الحاد، والتهاب الكبد الدهني غير الناتج عن تناول الكحوليات (NASH)، ومرض السكر، والسمنة، وما شابه ذلك.
JOP/2010/0453A 2009-12-24 2010-12-16 أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري JO3274B1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29009209P 2009-12-24 2009-12-24
US30635910P 2010-02-19 2010-02-19
US32831610P 2010-04-27 2010-04-27
US34927310P 2010-05-28 2010-05-28
US35612610P 2010-06-18 2010-06-18

Publications (1)

Publication Number Publication Date
JO3274B1 true JO3274B1 (ar) 2018-09-16

Family

ID=43629324

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0453A JO3274B1 (ar) 2009-12-24 2010-12-16 أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري

Country Status (30)

Country Link
US (2) US8354103B2 (ar)
EP (1) EP2516466B1 (ar)
JP (2) JP6000855B2 (ar)
KR (1) KR101842570B1 (ar)
CN (1) CN102741284A (ar)
AR (1) AR079708A1 (ar)
AU (1) AU2010336369C1 (ar)
BR (1) BR112012017765A2 (ar)
CA (1) CA2785158C (ar)
CY (1) CY1118898T1 (ar)
DK (1) DK2516466T3 (ar)
ES (1) ES2628135T3 (ar)
HR (1) HRP20170524T1 (ar)
HU (1) HUE034722T2 (ar)
IL (1) IL220402A (ar)
JO (1) JO3274B1 (ar)
LT (1) LT2516466T (ar)
MX (1) MX337082B (ar)
NZ (1) NZ600768A (ar)
PL (1) PL2516466T3 (ar)
PT (1) PT2516466T (ar)
RS (1) RS56009B1 (ar)
RU (1) RU2580045C2 (ar)
SG (1) SG181784A1 (ar)
SI (1) SI2516466T1 (ar)
SM (1) SMT201700280T1 (ar)
TW (1) TWI488643B (ar)
UY (1) UY33144A (ar)
WO (1) WO2011079257A2 (ar)
ZA (1) ZA201204507B (ar)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
AU2013245630A1 (en) * 2012-04-13 2014-10-30 The Johns Hopkins University Treatment of ischemic retinopathies
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
US9868777B2 (en) 2013-06-10 2018-01-16 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
KR101538787B1 (ko) * 2013-06-27 2015-07-22 인하대학교 산학협력단 췌장염 진단용 바이오 마커 조성물
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
WO2016020882A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
SG10201805646WA (en) * 2014-08-07 2018-08-30 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
US9556225B2 (en) * 2014-10-15 2017-01-31 Uniao Quimica Farmaceutica Nacional S/A Peptide stimulator of cell survival and proliferation
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
MX382035B (es) 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.
EP3565598A4 (en) * 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
WO2020191293A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
AU2020339478A1 (en) 2019-08-29 2021-05-06 Remegen Co., Ltd. Anti PD-L1 antibody and use thereof
AU2020399633A1 (en) * 2019-12-09 2022-07-07 Empirico Inc. Oligonucleotides for treatment of Angiopoietin like 4 (ANGPTL4) related diseases
WO2021173753A1 (en) 2020-02-26 2021-09-02 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
JP2023533253A (ja) * 2020-07-02 2023-08-02 マブリティクス， インコーポレイテッド 細胞結合タンパク質および使用の方法
WO2022006555A2 (en) * 2020-07-02 2022-01-06 Gigagen, Inc. BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
WO2023239307A1 (en) * 2022-06-10 2023-12-14 Nanyang Technological University Methods of treating liver fibrosis, inflammation or associated diseases using an angptl4 antagonist
CN119907693A (zh) * 2022-08-02 2025-04-29 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ES2371083T3 (es) * 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
BRPI0606432A2 (pt) 2005-01-07 2009-06-30 Lexicon Pharmaceuticals Inc anticorpos monoclonais contra angptl4
DK1962895T3 (da) 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
AU2007227251A1 (en) * 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Also Published As

Publication number Publication date
CA2785158A1 (en) 2011-06-30
AU2010336369A1 (en) 2012-07-12
MX337082B (es) 2016-02-11
ZA201204507B (en) 2013-02-27
NZ600768A (en) 2014-09-26
US20110159015A1 (en) 2011-06-30
SMT201700280T1 (it) 2017-07-18
IL220402A (en) 2016-10-31
RU2580045C2 (ru) 2016-04-10
LT2516466T (lt) 2017-05-25
KR20120104613A (ko) 2012-09-21
BR112012017765A2 (pt) 2017-06-20
EP2516466A2 (en) 2012-10-31
US9120851B2 (en) 2015-09-01
TWI488643B (zh) 2015-06-21
SI2516466T1 (sl) 2017-06-30
EP2516466B1 (en) 2017-03-15
SG181784A1 (en) 2012-07-30
RU2012131547A (ru) 2014-01-27
AU2010336369C1 (en) 2015-08-27
CY1118898T1 (el) 2018-01-10
UY33144A (es) 2011-06-30
US20130266574A1 (en) 2013-10-10
PL2516466T3 (pl) 2017-09-29
CA2785158C (en) 2018-07-24
DK2516466T3 (en) 2017-05-15
HRP20170524T1 (hr) 2017-06-02
AR079708A1 (es) 2012-02-15
JP6000855B2 (ja) 2016-10-05
WO2011079257A3 (en) 2011-08-18
RS56009B1 (sr) 2017-09-29
HUE034722T2 (en) 2018-02-28
TW201132354A (en) 2011-10-01
WO2011079257A2 (en) 2011-06-30
AU2010336369B2 (en) 2015-06-04
PT2516466T (pt) 2017-06-06
KR101842570B1 (ko) 2018-03-28
JP2013515486A (ja) 2013-05-09
MX2012007460A (es) 2012-08-23
ES2628135T3 (es) 2017-08-01
US8354103B2 (en) 2013-01-15
JP2015145424A (ja) 2015-08-13
CN102741284A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
BR112012017765A2 (pt) anticorpos humanos para proteína semelhante à angiopoietina humana-4
CY1120996T1 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201500064A1 (ru) Активаторы ampk и их применение в терапевтических целях
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EP2214480A4 (en) METHOD FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
FR2949044B1 (fr) Composition comprenant une fraction d'insaponifiable
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
UA103916C2 (xx) Антитіло проти dkk-1$антитело против dkk-1
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
MX2022001460A (es) Metodos para el tratamiento de enfermedades y trastornos relacionados con apoc3.
NO20083307L (no) Anvendelse av et ikke-forsapbart ekstrakt fra plantemasse ved behandling av hudaldring
ATE413167T1 (de) Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
EP2305300A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
EP1968559A4 (en) INFLAMMATORY BOTANICAL PRODUCTS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES
PH12012501279A1 (en) Human antibodies to human angiopoietin-like protein 4
UA94434C2 (ru) Экстракт коры дерева рода corynanthe и его применение, лекарственное средство, пищевой продукт с лекарственными или профилактическими свойствами и фармацевтический препарат, который его содержит
TN2013000490A1 (en) Anti-angptl3 antibodies and uses thereof
ATE412903T1 (de) Diagnostik- und therapie- verfahren von mit c5a rezeptor verbundenen krankheiten
TH147852A (th) แอนติบอดี้ชนิดต้าน angptl3 และการใช้ประโยชน์ของมัน